DXC Technology Co
Government Contracts & Awards
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
Private Placement
Market Intelligence & News
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
DXCM Grew. The Stock Did Not. Someone Is Wrong
The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.
The Quiet Case For A DXC Technology Takeover
The company is cheap and generates significant cash, but with ownership so widely spread, the only real question is who might make the first move.
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets
DexCom’s latest valuation work now centers on a fair value anchor of US$81.64, slightly below the prior US$83.54 level and closer to the current range of Street targets. Many firms have trimmed price targets after recent Analyst/Investor Day updates, reflecting a balance between confidence in execution and a more cautious stance on longer term growth and valuation assumptions. As you read on, you will see how these shifting targets, together with fresh guidance and product news, shape the...
Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It
Dexcom (DXCM) uses AI to boost margins and innovate CGM with Stelo for prediabetes.
Why Broadcom (AVGO) Is Becoming a Bigger Force in Custom AI Silicon
Broadcom Inc. (NASDAQ:AVGO) is one of the best AI enabler stocks to buy now. The latest AI infrastructure angle came on May 11, when SDxCentral reported that Blackstone and Apollo Global Management were in talks with Broadcom Inc. (NASDAQ:AVGO) over a financing deal of about $35 billion to support the company’s AI chipmaking buildout. The […]
Crude Oil Gains 1%; Fluor Shares Plunge After Q1 Results
US stocks traded higher, Nasdaq gained 1.5%. Dow down 0.06%. IT shares up 2.1% while healthcare stocks fell 0.9%. Fluor shares dropped 12% due to weak earnings. Westrock Coffee, Innodata, and Nlight shares rose. Artivion, DXC, and Kodiak AI shares fell. Oil up 1.1%, gold up 0.6%. European and Asian markets closed lower. US nonfarm payrolls beat estimates.
Congressional Trades in $DXC
Insider Trades (Form 4)
Del Bene Robert F
Voci Christopher Anthony
Ragone Jennifer
FAWCETT MATTHEW K
Venkataraman Ramanathan
August Raymond Alexander
Drumgoole Christopher
FERNANDEZ RAUL J
Key People
Del Bene Robert F
EVP, Chief Financial Officer
August Raymond Alexander
President, Insurance SW & Svcs
Ragone Jennifer
Chief People Officer
Venkataraman Ramanathan
EVP, CES
FAWCETT MATTHEW K
EVP and General Counsel
Voci Christopher Anthony
SVP, Controller and PAO
August Raymond Alexander
President, Insurance SW & Svcs
Drumgoole Christopher
EVP, GIS
FERNANDEZ RAUL J
President and CEO
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro